EACS2023: 505 Effectiveness and timing of viral load measurement in real-world use of long-acting cabotegravir-rilpivirine in people with HIV F. Fernandez-Hinojal , A. de Gea Grela , L. Martín-Carbonero , E. Valencia , R. Micán , C. Busca , L. Ramos , J.R. Arribas , J. González-Garcia , J.I. Bernardino , M.L. Montes Hospital Universitario La Paz, IdiPAZ, Internal Medicine Department / HIV Unit, Madrid, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Long-acting cabotegravir a nd rilpivirine (LA-C&R) have demonstrated efficacy, safety and improved quality of life of people living with HIV. However, there is a lack of data on effectiveness and follow-up in a real-world setting. This study aims to monitor the effectiveness of LA therapy at 3 and 6 months after switching from standard oral therapy and determine the optimal timing of viral load (VL) measurement after 2 or 3 injection after switch. Method: We conducted a retrospective observational unicenter study, including LA-C&R initiations between January to May 2023, excluding subjects from previous clinical trials. Viral load measurements were performed around the 2 or 3 LA administration, based on clinician discretion. Clinical and microbiological data was collected from medical records. Descriptive analysis of factors associated with VL ≥50 copies/mL was performed. Detailed comparison of viral loads will be provided in the final version. Results: Out of 139 subjects included in the study VL measurements were available in 61 participants at the time of analysis. Five participants had NNRTI resistance mutations. (Table 1). Following LA-C&R switch, 95% of subjects had undetectable VL (<50 copies/mL). All participants with detectable VL (≥50 copies/mL) had experienced blips two years prior to the analysis and the proportion of blips was similar regardless of the timing of VL measurement (<45 or >45 days after LA initiation). Within this subgroup, three subjects had detectable VL in the 1 month, but remained undetectable during follow-up. Four subjects had detectable VL prior to switch; three remained undetectable after switching. (Table 2). Conclusions: LA-C&R therapy appeared effective in the short-term even in PLWH with exclusion criteria from clinical trials, with cautious considerations for individuals with previous blips. Our findings suggest that timing of VL measurement did not impact the results. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 1 1 1 1 1 nd rd nd rd st 127
RkJQdWJsaXNoZXIy Mzc2ODc=